Profil
Suk Ping Lam served as an Executive Director at China Ruyi Holdings Ltd.
from 2010 to 2011.
He was also an Independent Non-Executive Director at Goldstone Investment Group Ltd.
in 2011 and at Mingyuan Medicare Development Co. Ltd.
from 2016 to 2020.
He served as the Chief Financial Officer at OCI International Holdings Ltd.
Mr. Lam holds an MBA from The University of Hull and a graduate degree from Hong Kong Metropolitan University.
Anciens postes connus de Suk Ping Lam
| Sociétés | Poste | Fin |
|---|---|---|
| MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Director/Board Member | 22/01/2020 |
| GOLDSTONE INVESTMENT GROUP LIMITED | Director/Board Member | 20/10/2011 |
| CHINA RUYI HOLDINGS LIMITED | Director/Board Member | 27/04/2011 |
| OCI INTERNATIONAL HOLDINGS LIMITED | Director of Finance/CFO | - |
Formation de Suk Ping Lam
| The University of Hull | Masters Business Admin |
| Hong Kong Metropolitan University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CHINA RUYI HOLDINGS LIMITED | Miscellaneous |
| GOLDSTONE INVESTMENT GROUP LIMITED | Finance |
| OCI INTERNATIONAL HOLDINGS LIMITED | Finance |
| Entreprise privées | 1 |
|---|---|
Mingyuan Medicare Development Co. Ltd.
 Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
